The Globe and Mail: Grifols donors not informed their plasma is used for drugs sold overseas, MPs hear
Donors giving blood plasma at Grifols’ paid collection centres are not informed that some medicines made from their donations will be sold for profit overseas, according to testimony from a Canadian ...
Grifols donors not informed their plasma is used for drugs sold overseas, MPs hear
Canadian health officials imposed restrictions on all plasma centers run by Grifols (GRFS) after the Spanish company failed multiple regulatory inspections and following fatal adverse reactions in two ...
Grifols, a Spanish health care company, operates clinics in Canada that collect blood plasma from donors in exchange for an honorarium. By Vjosa Isai and Roni Caryn Rabin Vjosa Isai reported from ...
Spanish drugmaker Grifols SA is facing restrictions on its Canadian licence to collect blood products following the deaths of two patients who made plasma donations in the country. Health Canada, ...
The Globe and Mail: Health Canada imposes new conditions on Grifols after deaths of two people who donated plasma
Health Canada is imposing new terms and conditions on the licences of Grifols, Canada’s only major commercial collector of blood plasma, after two people died following donations in recent months. The ...
Health Canada imposes new conditions on Grifols after deaths of two people who donated plasma
Calgary Herald: Grifols plasma collection site in Calgary slapped with regulatory non-compliance ratings
Spanish drugmaker Grifols SA is facing restrictions on its Canadian licence to collect blood products following the deaths of two patients who made plasma donations in the country. Health Canada, the ...
InfoWorld: Comparing Angular, React, Vue, and Svelte: What you need to know
These four reactive frameworks are all popular options for building dynamic, scalable web apps in JavaScript. Here's help choosing the right one for you. The last time I compared the leading reactive ...
Grifols is a leading global healthcare company. Our trusted and innovative plasma-derived medicines, other biopharmaceuticals and solutions in transfusion medicine enable millions of patients around the world to lead more productive lives.
Descubre las innovadoras soluciones biofarmacéuticas y sanitarias integrales de Grifols centradas en el paciente.
Explore Grifols Poland, a leader in biotechnology and healthcare, dedicated to improving patient lives through innovative therapies and high-quality services.
Grifols is a global healthcare company that has enhanced the health and well-being of people around the world.
Join Grifols to create a lasting impact with your career. Explore opportunities that allow you to contribute to life-saving solutions and innovate for a healthier future.
Grifols is also a leader in transfusion medicine, helping ensure the safety of the world’s blood supply. In addition, we provide biological materials, including plasma, for life-science research and further manufacturing, and the company has a comprehensive portfolio of tools, information and services that enable hospitals to efficiently ...
We trace our roots back to 1909 when Dr. Josep Antoni Grifols i Roig founded the first analysis laboratory in Barcelona: Instituto Central de Análisis Clínicos, Bacteriológicos y Químicos.
The sale of a minority stake of its U.S. Biopharma business by means of an initial public offering (IPO) would raise capital to strengthen the Group’s balance sheet, reduce debt and support investment in its strategic growth priorities, while allowing Grifols to maintain majority ownership of its U.S. Biopharma business The proposed transaction reinforces Grifols’ self-sufficiency vision ...
Contact Grifols for inquiries and support. Our team is here to assist you with information and resources tailored to your needs.
Explore Grifols France for cutting-edge pharmacovigilance and comprehensive medical information to enhance patient safety and treatment outcomes.
TO THE FULLEST EXTENT PERMISSIBLE PURSUANT TO APPLICABLE LAW, Neighborhood Link DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.
The Globe and Mail: Grifols Refinances 2027 Debt and Extends Maturities with Multi-Billion Term Loan B Package
Detailed price information for Grifols S.A. ADR (GRFS-Q) from The Globe and Mail including charting and trades.
Grifols Refinances 2027 Debt and Extends Maturities with Multi-Billion Term Loan B Package
Yahoo Finance UK: Assessing Grifols (BME:GRF) Valuation After Recent Share Price Weakness And Perceived Discount
Recent performance context for Grifols Grifols (BME:GRF) has drawn investor attention after a mixed run, with a modest 1 day gain, a negative move over the past week and month, and a deeper decline ...
Assessing Grifols (BME:GRF) Valuation After Recent Share Price Weakness And Perceived Discount
Jan 9 (Reuters) - Spanish drugmaker Grifols, whose shares slumped on Tuesday after hedge fund Gotham City Research questioned its accounts, has grown from a family-run blood testing lab founded in ...
The Corner: Grifols plans to make early repayment of €500 million of its 7.5% secured bonds maturing in 2030
Link Securities | Grifols (GRF) plans to make an early repayment of €500 million of its 7.5% senior secured bonds maturing in 2030. This transaction would ...
Grifols plans to make early repayment of €500 million of its 7.5% secured bonds maturing in 2030
Spanish plasma-derived medicines company Grifols announced that it has successfully completed the refinancing of its 2027 debt maturities through a new credit agreement structured as a Term Loan B ...
Yahoo Finance: Does Grifols (BME:GRF) Offer Opportunity After Sharp Share Price Declines And Debt Concerns
Does Grifols (BME:GRF) Offer Opportunity After Sharp Share Price Declines And Debt Concerns
MADRID (Reuters) -Spanish drugmaker Grifols has taken a 457 million euros ($494 million) writedown on its accounts for 2020 through 2023, to reflect what it says was a previously incorrect accounting ...
Grifols (NASDAQ:GRFS) shares shot up by nearly 22% in the premarket session today. The surge followed an approach by its founding family and Brookfield to acquire and delist the Spanish pharmaceutical ...
Seeking Alpha: Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
The addition of the Clayton site in 2011 marked a new milestone for Grifols (GRFS), turning the company into a top-three plasma industry leader and setting the stage for sustained business growth The ...
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.